Heyman Richard A.'s Form 4 filing
Enliven Therapeutics, Inc. (ELVN) · filed Dec 26, 2023
- Accession no.
- 0001209191-23-059715
- Filed
- Dec 26, 2023
- Trade date
- Dec 21-22, 2023
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions. Open-market sales total $2.81K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Heyman Richard A.CIK 0001584759 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 21, 2023 | Common Stock | SSaleDisposed | −7 | $13.00 | −$91 | 147,448 | Direct | |
| Dec 21, 2023 | Common Stock | SSaleDisposed | −6 | $13.00 | −$78 | 29,251 | Indirect | |
| Dec 22, 2023 | Common Stock | SSaleDisposed | −168 | $13.00 | −$2,184 | 147,280 | Direct | |
| Dec 22, 2023 | Common Stock | SSaleDisposed | −35 | $13.00 | −$455 | 29,216 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.